Radar Therapeutics Raises $13.4M in Funding for Smart Medicines Development
Radar Therapeutics Raises $13.4M in Seed Funding
Radar Therapeutics Raises $13.4M in Seed Funding
Key Highlights:
- Seed Funding: Radar Therapeutics, a biotech company developing smart programmable medicines, raised $13.4M in a recent funding round.
- Investors: NfX Bio led the round, with participation from Eli Lilly and Company, Biovision Ventures, KdT Ventures, PearVC, BEVC, and other investors.
- Company Focus: Radar Therapeutics is developing programmable genetic and mRNA-based therapeutics that enable targeted and timed delivery of drug payloads into specific cells.
Radar Therapeutics' Target Market
- Biotech and Pharmaceutical Companies: Potential partners and collaborators in the development and commercialization of smart programmable medicines.
- Research Institutions and Universities: Academic institutions conducting research in genetic and mRNA-based therapeutics.
- Investors and Venture Capital Firms: Entities interested in supporting innovative biotech companies and precision therapeutics.
What Radar Therapeutics Needs to Buy
- Research and Development Services: Collaborations with research organizations and experts in genetic and mRNA-based therapeutics.
- Manufacturing and Supply Chain Solutions: Partnerships with manufacturers and suppliers for the production and distribution of programmable medicines.
- Strategic Partnerships: Collaborations with biotech and pharmaceutical companies for joint research, development, and commercialization efforts.